Anthracyclines and trastuzumab associated cardiotoxicity: is the gut microbiota a friend or foe? – a mini-review
Breast cancer (BC) is one of the most prevalent cancers worldwide. Fortunately, BC treatment has taken a huge turn in the last few years. Despite these advances, one of the main issues related to systemic treatment remains the management of its side effects, including cardiotoxicity. In this regard,...
Main Authors: | J. Guilherme Gonçalves-Nobre, Inês Gaspar, Diogo Alpuim Costa |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Microbiomes |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/frmbi.2023.1217820/full |
Similar Items
-
The potential links between human gut microbiota and cardiovascular health and disease - is there a gut-cardiovascular axis?
by: Cátia Almeida, et al.
Published: (2023-10-01) -
Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review
by: Diogo Alpuim Costa, et al.
Published: (2023-09-01) -
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
by: Pooja P. Advani, et al.
Published: (2023-05-01) -
Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters
by: Belén Díaz‐Antón, et al.
Published: (2022-04-01) -
Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity
by: Aleksandra M. Sobiborowicz-Sadowska, et al.
Published: (2023-01-01)